University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity

Researchers are encouraged and excited by study results in healthy adults.

MIAMI, Aug. 15, 2012 /PRNewswire/ -- A published University of Miami study using Rice Bran Arabinoxylan Compound (RBAC) has showed  RBAC demonstrated significant immunomodulary activity based upon the observed changes in natural killer cell cytotoxicity (NKCC) and the cytokines and growth factors. Specifically, the study showed that the short term rise in NKCC and in 9 of 12 cytokines and growth factors are evident that RBAC is a potent immunomodulator. The study was published July 28, 2012 in Functional Foods in Health and Disease (Volume 2, Issue 7), http://functionalfoodscenter.net/The_Journal_of_FFHD__Page_3.html.

RBAC may help to destroy tumor cells and viruses directly, and increase the activity of immune cells, thereby optimizing the immune system, especially NKCC, which can increase the chance and speed of host recovery. Researchers note that the immunomodulatory activity merits further study in conditions where the immune system is functionally compromised, such as otherwise healthy smokers and HIV/AIDS or cancer patients.

RBAC is a nutritional supplement produced by enzymatic hydrolysis of hemicellulose B derived from rice bran. Several in vitro studies and clinical reports have shown RBAC to possess promising immunomodulating effects, specifically with respect to natural killer cell and cytokine activity.

The concept of a true immunomodulator is an agent possessing a broad range of activity dependent upon the existing state of health and immunity in the individual host. The Miami University study investigated the immunomodulatory effect of RBAC in a healthy adult human population over 60 days by assessing changes in NKCC and cytokines and growth factors.

According to Dr. John Lewis, Ph.D. associate professor, department of psychiatry and behavioral sciences at the University of Miami, Miller School of Medicine, and corresponding research author, this study represents a first step in testing this product in healthy adults. 

"We showed that the product is safe according to protein, bilirubin, and liver function tests, and that RBAC is capable of true immunomodulation, not stimulation or suppression," said Dr. Lewis. "In other words, the immune factors that we analyzed showed bi-directional, transient responses in people who were healthy without chronic disease," Dr. Lewis added.

"Our results are valid based on the statistical analysis that we performed in the study and appear to be consistent with the findings of other investigators as well," said Dr. Lewis.

The study was sponsored by Gardena, CA-based Daiwa Health Development. RBAC product for this study was supplied by Daiwa Health Development.

Dr. Aaron H. Wolfson, M.D., professor and vice chairman of the department of radiation oncology at the University of Miami, Miller School of Medicine, co-author in the study, and a proponent of RBAC since 2002, added, "we are eagerly looking to expand the use of RBAC in patients with end stage solid tumors (cancers) in the near future in a phase one trial as a preliminary study to evaluate PeakImunne4 as a potential therapeutic agent in treating these terminal patients."

RBAC is manufactured by Daiwa Health Development, and sold commercially as PeakImmune4®, an essential, broad spectrum immune support dietary supplement providing vital antioxidant and anti-inflammatory action. RBAC is a polysaccharide dietary fiber derived from rice bran and is modified by an enzyme from Shiitake mushrooms using a patented biotechnology process.

Daiwa has become a leading research and manufacturing company, striving to create new value in the field of bioscience in the U.S. and worldwide.

For complete study information call 877.434.3633 or email Info@DHDMED.com.

 

For more Information:
Karena Dillon
Baker Dillon Group
Info@BakerDillon.com 
559.325.7191

 

SOURCE Daiwa Health Development

 

Posted: August 2012

View comments

Hide
(web1)